Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics Inc. demonstrates promising potential due to the novel features of its clinical-stage anti-VEGF drug, TH103, which exhibits superior retinal retention compared to existing therapies such as Eylea, suggesting extended durability for patients. The company benefits from the strong market performance of anti-VEGF treatments, as illustrated by Vabysmo surpassing $4 billion in global sales within its third year, indicating a significant opportunity for incremental advancements in this sector. Additionally, preclinical findings indicating complete inhibition of VEGF-induced endothelial cell proliferation provide a favorable outlook for TH103, positioning Kalaris Therapeutics to potentially capture market share in the growing field of retinal disease therapeutics.

Bears say

Kalaris Therapeutics Inc. faces significant financial challenges, as the company has yet to commercialize any products and is projected to continue incurring net losses until at least the early launch phase of its lead candidate, TH103. The competitive landscape poses additional risks, with existing and emerging therapies potentially hindering market penetration and affecting pricing strategies. Furthermore, the possibility of delays in clinical development and regulatory approvals could prolong the timeline and increase costs, compounding the financial risks for Kalaris.

Allovir Inc (KLRS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 4 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.